{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T15:45:45Z","timestamp":1792856745446,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Stroke is an important contributor to disability and death globally. Hypertension is a main risk factor for recurrent stroke in patients with ischemic and hemorrhagic stroke or transient ischemic attack. Higher systolic blood pressure, diastolic blood pressure, pulse pressure and mean arterial pressure at admission are independently associated with the risk of stroke recurrence. Therefore, lowering blood pressure is recommended by guidelines to prevent the recurrence of stroke.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic search of PubMed, Embase, Cochrane Central Register of Controlled Trials, and Web of Science databases was conducted through January 12, 2024. The search identified randomized controlled trials (RCTs) comparing antihypertensive drugs with control measures (placebo or no treatment) or standard blood pressure control (SBPC) with intensive blood pressure control (IBPC) for recurrent stroke prevention. Primary outcomes included overall and subtype stroke recurrence rates, fatal and non-fatal strokes, cardiovascular deaths, and myocardial infarctions (MIs). Secondary outcomes comprised non-fatal MIs and all-cause mortality. Risk ratios (RRs) and 95% confidence intervals (CIs) were calculated using random or fixed-effect models in Stata 15.0.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The analysis included 19 RCTs encompassing 72,048 patients. Twelve studies (n\u2009=\u200953,971) evaluated antihypertensive drugs against placebo or no treatment, while seven studies (n\u2009=\u200918,077) compared SBPC with IBPC. Antihypertensive therapy demonstrated significant risk reductions compared to placebo or no treatment for recurrent stroke (RR\u2009=\u20090.86, 95% CI: 0.75\u20130.97), cardiovascular deaths (RR\u2009=\u20090.92, 95% CI: 0.87\u20130.97), and MIs (RR\u2009=\u20090.87, 95% CI: 0.79\u20130.96). IBPC showed superior outcomes compared to SBPC, with significant reductions in recurrent stroke (RR\u2009=\u20090.87, 95% CI: 0.77\u20130.98), cardiovascular deaths (RR\u2009=\u20090.75, 95% CI: 0.61\u20130.91), and all-cause mortality (RR\u2009=\u20090.85, 95% CI: 0.73\u20130.95).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In stroke patients, antihypertensive therapy demonstrates significant protective effects against stroke recurrence, cardiovascular deaths, and MIs compared to placebo or no treatment. Additionally, IBPC provides enhanced protection against stroke recurrence, cardiovascular deaths, and all-cause mortality compared to SBPC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40001-024-02226-3","type":"journal-article","created":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T22:00:00Z","timestamp":1736373600000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Antihypertensive strategies for the prevention of secondary stroke: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"30","author":[{"given":"ChunQi","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ShuangYan","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ZhiQiang","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YiPing","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,9]]},"reference":[{"issue":"5","key":"2226_CR1","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1001\/jamaneurol.2023.0218","volume":"80","author":"CY Hsu","year":"2023","unstructured":"Hsu CY, Saver JL, Ovbiagele B, Wu YL, Cheng CY, Lee M. Association between magnitude of differential blood pressure reduction and secondary stroke prevention: a meta-analysis and meta-regression. JAMA Neurol. 2023;80(5):506\u201315. https:\/\/doi.org\/10.1001\/jamaneurol.2023.0218.","journal-title":"JAMA Neurol"},{"issue":"6","key":"2226_CR2","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1161\/strokeaha.116.012944","volume":"47","author":"S Mustanoja","year":"2016","unstructured":"Mustanoja S, Putaala J, Gordin D, Tulkki L, Aarnio K, Pirinen J, et al. Acute-phase blood pressure levels correlate with a high risk of recurrent strokes in young-onset ischemic stroke. Stroke. 2016;47(6):1593\u20138. https:\/\/doi.org\/10.1161\/strokeaha.116.012944.","journal-title":"Stroke"},{"key":"2226_CR3","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/s1474-4422(18)30499-x","volume":"18","author":"GBD 2016 Stroke Collaborators","year":"2019","unstructured":"GBD 2016 Stroke Collaborators. Global, regional, and national burden of stroke, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18:439\u201358. https:\/\/doi.org\/10.1016\/s1474-4422(18)30499-x.","journal-title":"Lancet Neurol"},{"key":"2226_CR4","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1161\/circresaha.116.308413","volume":"120","author":"VL Feigin","year":"2017","unstructured":"Feigin VL, Norrving B, Mensah GA. Global burden of stroke. Circ Res. 2017;120:439\u201348. https:\/\/doi.org\/10.1161\/circresaha.116.308413.","journal-title":"Circ Res"},{"key":"2226_CR5","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.genhosppsych.2020.06.011","volume":"66","author":"GC Medeiros","year":"2020","unstructured":"Medeiros GC, Roy D, Kontos N, Beach SR. Post-stroke depression: a 2020 updated review. Gen Hosp Psychiatry. 2020;66:70\u201380. https:\/\/doi.org\/10.1016\/j.genhosppsych.2020.06.011.","journal-title":"Gen Hosp Psychiatry"},{"key":"2226_CR6","doi-asserted-by":"publisher","first-page":"Cd007858","DOI":"10.1002\/14651858.CD007858.pub2","volume":"7","author":"TP Zonneveld","year":"2018","unstructured":"Zonneveld TP, Richard E, Vergouwen MD, Nederkoorn PJ, de Haan R, Roos YB, et al. Blood pressure-lowering treatment for preventing recurrent stroke, major vascular events, and dementia in patients with a history of stroke or transient ischaemic attack. Cochrane Database Syst Rev. 2018;7:Cd007858. https:\/\/doi.org\/10.1002\/14651858.CD007858.pub2.","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"2226_CR7","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/s0140-6736(13)60852-1","volume":"38","author":"OR Benavente","year":"2013","unstructured":"Benavente OR, Coffey CS, Conwit R, Hart RG, McClure LA, Pearce LA, et al. Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet. 2013;38(2):507\u201315. https:\/\/doi.org\/10.1016\/s0140-6736(13)60852-1.","journal-title":"Lancet"},{"key":"2226_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i708","volume":"352","author":"J Mant","year":"2016","unstructured":"Mant J, McManus RJ, Roalfe A, Fletcher K, Taylor CJ, Martin U, et al. Different systolic blood pressure targets for people with history of stroke or transient ischaemic attack: PAST-BP (prevention after stroke-blood pressure) randomised controlled trial. BMJ. 2016;352: i708. https:\/\/doi.org\/10.1136\/bmj.i708.","journal-title":"BMJ"},{"key":"2226_CR9","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1001\/jamaneurol.2019.2167","volume":"76","author":"K Kitagawa","year":"2019","unstructured":"Kitagawa K, Yamamoto Y, Arima H, Maeda T, Sunami N, Kanzawa T, et al. Effect of standard vs intensive blood pressure control on the risk of recurrent stroke: a randomized clinical trial and meta-analysis. JAMA Neurol. 2019;76:1309\u201318. https:\/\/doi.org\/10.1001\/jamaneurol.2019.2167.","journal-title":"JAMA Neurol"},{"key":"2226_CR10","doi-asserted-by":"publisher","first-page":"3g","DOI":"10.1016\/s0002-9149(03)00226-1","volume":"91","author":"J Chalmers","year":"2003","unstructured":"Chalmers J. Trials on blood pressure-lowering and secondary stroke prevention. Am J Cardiol. 2003;91:3g\u20138g. https:\/\/doi.org\/10.1016\/s0002-9149(03)00226-1.","journal-title":"Am J Cardiol"},{"key":"2226_CR11","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/s0140-6736(11)60104-9","volume":"377","author":"EC Sandset","year":"2011","unstructured":"Sandset EC, Bath PM, Boysen G, Jatuzis D, K\u00f5rv J, L\u00fcders S, et al. The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial. Lancet. 2011;377:741\u201350. https:\/\/doi.org\/10.1016\/s0140-6736(11)60104-9.","journal-title":"Lancet"},{"key":"2226_CR12","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/s0140-6736(01)06178-5","volume":"358","author":"PROGRESS Collaborative Group","year":"2001","unstructured":"PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033\u201341. https:\/\/doi.org\/10.1016\/s0140-6736(01)06178-5.","journal-title":"Lancet"},{"key":"2226_CR13","doi-asserted-by":"publisher","unstructured":"Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke. The Dutch TIA Trial Study Group. Stroke. 1993;24:543\u201348. https:\/\/doi.org\/10.1161\/01.str.24.4.543","DOI":"10.1161\/01.str.24.4.543"},{"key":"2226_CR14","doi-asserted-by":"publisher","first-page":"3541","DOI":"10.1161\/strokeaha.109.555623","volume":"40","author":"PM Bath","year":"2009","unstructured":"Bath PM, Martin RH, Palesch Y, Cotton D, Yusuf S, Sacco R, et al. Effect of telmisartan on functional outcome, recurrence, and blood pressure in patients with acute mild ischemic stroke: a PRoFESS subgroup analysis. Stroke. 2009;40:3541\u20136. https:\/\/doi.org\/10.1161\/strokeaha.109.555623.","journal-title":"Stroke"},{"key":"2226_CR15","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1038\/hr.2009.139","volume":"32","author":"L Liu","year":"2009","unstructured":"Liu L, Wang Z, Gong L, Zhang Y, Thijs L, Staessen JA, et al. Blood pressure reduction for the secondary prevention of stroke: a Chinese trial and a systematic review of the literature. Hypertens Res. 2009;32:1032\u201340. https:\/\/doi.org\/10.1038\/hr.2009.139.","journal-title":"Hypertens Res"},{"key":"2226_CR16","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","volume":"373","author":"JT Wright Jr","year":"2015","unstructured":"Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373:2103\u201316. https:\/\/doi.org\/10.1056\/NEJMoa1511939.","journal-title":"N Engl J Med"},{"key":"2226_CR17","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1056\/nejm200001203420301","volume":"342","author":"S Yusuf","year":"2000","unstructured":"Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145\u201353. https:\/\/doi.org\/10.1056\/nejm200001203420301.","journal-title":"N Engl J Med"},{"key":"2226_CR18","first-page":"710","volume":"108","author":"PATS Collaborating Group","year":"1995","unstructured":"PATS Collaborating Group. Post-stroke antihypertensive treatment study. A preliminary result. Chin Med J (Engl). 1995;108:710\u20137.","journal-title":"Chin Med J (Engl)"},{"key":"2226_CR19","doi-asserted-by":"publisher","unstructured":"Effect of antihypertensive treatment on stroke recurrence. Hypertension-Stroke Cooperative Study Group. Jama. 1974; 229:409\u201318. https:\/\/doi.org\/10.1001\/jama.1974.03230420021019.","DOI":"10.1001\/jama.1974.03230420021019"},{"key":"2226_CR20","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1056\/NEJMoa0804593","volume":"359","author":"S Yusuf","year":"2008","unstructured":"Yusuf S, Diener HC, Sacco RL, Cotton D, Ounpuu S, Lawton WA, et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med. 2008;359:1225\u201337. https:\/\/doi.org\/10.1056\/NEJMoa0804593.","journal-title":"N Engl J Med"},{"key":"2226_CR21","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1291\/hypres.27.147","volume":"27","author":"Y Hasegawa","year":"2004","unstructured":"Hasegawa Y, Yamaguchi T, Omae T, Woodward M, Chalmers J. Effects of perindopril-based blood pressure lowering and of patient characteristics on the progression of silent brain infarct: the Perindopril Protection against Recurrent Stroke Study (PROGRESS) CT Substudy in Japan. Hypertens Res. 2004;27:147\u201356. https:\/\/doi.org\/10.1291\/hypres.27.147.","journal-title":"Hypertens Res"},{"key":"2226_CR22","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1161\/hypertensionaha.115.06480","volume":"67","author":"MC Odden","year":"2016","unstructured":"Odden MC, McClure LA, Sawaya BP, White CL, Peralta CA, Field TS, et al. Achieved blood pressure and outcomes in the secondary prevention of small subcortical strokes trial. Hypertension. 2016;67:63\u20139. https:\/\/doi.org\/10.1161\/hypertensionaha.115.06480.","journal-title":"Hypertension"},{"key":"2226_CR23","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/s0140-6736(70)91577-1","volume":"1","author":"AB Carter","year":"1970","unstructured":"Carter AB. Hypotensive therapy in stroke survivors. Lancet. 1970;1:485\u20139. https:\/\/doi.org\/10.1016\/s0140-6736(70)91577-1.","journal-title":"Lancet"},{"key":"2226_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0164608","volume":"12","author":"PM Bath","year":"2017","unstructured":"Bath PM, Scutt P, Blackburn DJ, Ankolekar S, Krishnan K, Ballard C, et al. Intensive versus guideline blood pressure and lipid lowering in patients with previous stroke: main results from the pilot \u201cprevention of decline in cognition after stroke trial\u201d (PODCAST) randomised controlled trial. PLoS ONE. 2017;12: e0164608. https:\/\/doi.org\/10.1371\/journal.pone.0164608.","journal-title":"PLoS ONE"},{"issue":"1","key":"2226_CR25","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1159\/000107813","volume":"5","author":"S Eriksson","year":"1995","unstructured":"Eriksson S, Olofsson B-O, Wester P-O. Atenolol in secondary prevention after stroke. Cerebrovasc Dis. 1995;5(1):21\u20135. https:\/\/doi.org\/10.1159\/000107813.","journal-title":"Cerebrovasc Dis"},{"key":"2226_CR26","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41440-022-00862-y","volume":"45","author":"K Kitagawa","year":"2022","unstructured":"Kitagawa K, Arima H, Yamamoto Y, Ueda S, Rakugi H, Kohro T, et al. Intensive or standard blood pressure control in patients with a history of ischemic stroke: RESPECT post hoc analysis. Hypertens Res. 2022;45:591\u2013601. https:\/\/doi.org\/10.1038\/s41440-022-00862-y.","journal-title":"Hypertens Res"},{"key":"2226_CR27","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1161\/01.str.28.12.2557","volume":"28","author":"F Gueyffier","year":"1997","unstructured":"Gueyffier F, Boissel JP, Boutitie F, Pocock S, Coope J, Cutler J, et al. Effect of antihypertensive treatment in patients having already suffered from stroke. Gathering the evidence. The INDANA (INdividual Data ANalysis of Antihypertensive intervention trials) Project Collaborators. Stroke. 1997;28:2557\u201362. https:\/\/doi.org\/10.1161\/01.str.28.12.2557.","journal-title":"Stroke"},{"issue":"7","key":"2226_CR28","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1161\/01.Str.0000075777.18006.89","volume":"34","author":"J Schrader","year":"2003","unstructured":"Schrader J, L\u00fcders S, Kulschewski A, Berger J, Zidek W, Treib J, et al. The ACCESS study: evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke. 2003;34(7):1699\u2013703. https:\/\/doi.org\/10.1161\/01.Str.0000075777.18006.89.","journal-title":"Stroke"},{"issue":"9","key":"2226_CR29","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1586\/erc.11.132","volume":"9","author":"N Tanahashi","year":"2011","unstructured":"Tanahashi N, Nakagawara J, Okada Y, Minematsu K. Candesartan cilexetil in the management of blood pressure for acute and recurrent stroke in Japan: the Challenge-Stroke study. Expert Rev Cardiovasc Ther. 2011;9(9):1115\u201326. https:\/\/doi.org\/10.1586\/erc.11.132.","journal-title":"Expert Rev Cardiovasc Ther"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-024-02226-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-024-02226-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-024-02226-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T22:04:58Z","timestamp":1736373898000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-024-02226-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,9]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2226"],"URL":"https:\/\/doi.org\/10.1186\/s40001-024-02226-3","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,9]]},"assertion":[{"value":"10 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18"}}